Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active Disease

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lodi, Alessia ^a,b   Tiziani, Stefano ^a,b,c   Khanim, Farhat L ^a   Günther, Ulrich L ^a   Viant, Mark R ^a   Morgan, Gareth J ^d   Bunce, Christopher M ^a   Drayson, Mark T ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRIC ACID; 3 HYDROXY 2 METHYLPROPIONIC ACID; 3 HYDROXYBUTYRIC ACID; ACETYLCARNITINE; ALANINE; BIOLOGICAL MARKER; CARNITINE; CHOLINE; CREATININE; GLUCOSE; HYDROXYBUTYRIC ACID; SUCCINIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLITE; METABOLOMICS; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; PROTEIN ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; URINALYSIS;

ACETYLCARNITINE; AGED; AGED, 80 AND OVER; CARNITINE; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874196888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056422     Document Type: Article

References (52)

1. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, et al. (2011) The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res 110: 19-42.
2. Palumbo A, Anderson K, (2011) Multiple myeloma. N Engl J Med 364: 1046-1060.
3. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, et al. (2009) Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 94: 380-386.
4. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, et al. (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28: 4976-4984.
5. Minter AR, Simpson H, Weiss BM, Landgren O, (2011) Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. Semin Hematol 48: 55-65.
6. Roodman GD, (2009) Pathogenesis of myeloma bone disease. Leukemia 23: 435-441.
7. Drayson M, Begum G, Basu S, Makkuni S, Dunn J, et al. (2006) Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 108: 2013-2019.
8. Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, et al. (2008) High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 26: 2240-2243.
9. Rajkumar SV, (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8: 479-491.
10. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, et al. (2011) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 29: 1916-1923.
11. van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, et al. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 37: 266-283.
12. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, et al. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24: 1121-1127.
13. Kyle RA, Rajkumar SV, (2010) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep 5: 62-69.
14. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, et al. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471: 467-472.
15. MacIntyre DA, Jimenez B, Lewintre EJ, Martin CR, Schafer H, et al. (2010) Serum metabolome analysis by H-1-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 24: 788-797.
16. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, et al. (2005) Detection of epithelial ovarian cancer using H-1-NMR-based metabonomics. Int J Cancer 113: 782-788.
17. Tiziani S, Lopes V, Gunther UL, (2009) Early Stage Diagnosis of Oral Cancer Using H-1 NMR-Based Metabolomics. Neoplasia 11: 269-U269.
18. Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E, (2003) Application of chemometrics to H-1 NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128: 32-36.
19. Ludwig C, Ward DG, Martin A, Viant MR, Ismail T, et al. (2009) Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn Reson Chem 47: S68-S73.
20. Whitehead TL, Kieber-Emmons T, (2005) Applying in vitro NMR spectroscopy and H-1 NMR metabonomics to breast cancer characterization and detection. Prog Nucl Magn Reson Spectrosc 47: 165-174.
21. Gao HC, Dong BJ, Liu X, Xuan HQ, Huang YR, et al. (2008) Metabonomic profiling of renal cell carcinoma: High-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta 624: 269-277.
22. Barton RH, Nicholson JK, Elliott P, Holmes E, (2008) High-throughput H-1 NMR-based metabolic analysis of human serum and urine for large-scale epidemiological studies: validation study. Int J Epidemiol 37: 31-40.
23. Holmes E, Wilson ID, Nicholson JK, (2008) Metabolic phenotyping in health and disease. Cell 134: 714-717.
24. Tiziani S, Emwas AH, Lodi A, Ludwig C, Bunce CM, et al. (2008) Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal Biochem 377: 16-23.
25. Beckonert O, Keun HC, Ebbels TMD, Bundy JG, Holmes E, et al. (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2: 2692-2703.
26. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, et al. (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119: 7-15.
27. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, et al. (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118: 1231-1238.
28. Parsons HM, Ludwig C, Günther UL, Viant MR, (2007) Improved classification accuracy in 1-and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics 8: 234.
29. Hwang TL, Shaka AJ, (1995) Water suppression that works- Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J Magn Reson Ser A 112: 275-279.
30. Dieterle F, Ross A, Schlotterbeck G, Senn H, (2006) Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in H-1 NMR metabonomics. Anal Chem 78: 4281-4290.
31. Günther UL, Ludwig C, Ruterjans H, (2000) NMRLAB- Advanced NMR data processing in MATLAB J Magn Reson. 145: 201-208.
32. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, et al. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometr 20: 341-351.
33. Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, et al. (2008) Assessment of PLSDA cross validation. Metabolomics 4: 81-89.
34. Holmes E, Loo RL, Cloarec O, Coen M, Tang HR, et al. (2007) Detection of urinary drug metabolite (Xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal Chem 79: 2629-2640.
35. Kuliszkiewiczjanus M, Baczynski S, (1995) Chemotherapy-associated chnages in P-31 MRS spectra of sera from patients with multiple-myeloma. NMR Biomed 8: 127-132.
36. Holub BJ (1986) Metabolism and function of myo-inositol and inositol phospholipids. In: Olson RE, editor. Annual Review of Nutrition Palo Alto, Calif., USA.: Annual Reviews Inc. 563-598.
37. Li X, Xu ZL, Lu X, Yang XH, Yin PY, et al. (2009) Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta 633: 257-262.
38. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, et al. (2010) alpha-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population. PLoS One 5.
39. Athanassakis I, Mouratidou M, Sakka P, Evangeliou A, Spilioti M, et al. (2001) L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol 1: 1813-1822.
40. Khoo SHG, Al-Rubeai M, (2009) Metabolic characterization of a hyper-productive state in an antibody producing NS0 myeloma cell line. Metab Eng 11: 199-211.
41. Hoppel C, (2003) The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 41: S4-S12.
42. Siliprandi N, Sartorelli L, Ciman M, Di Lisa F, (1989) Carnitine: Metabolism and clinical chemistry Clin Chim Acta. 183: 3-11.
43. Ramsay RR, Gandour RD, van der Leij FR, (2001) Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta-Protein Struct Molec Enzym 1546: 21-43.
44. Radin NS, (2003) Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J 371: 243-256.
45. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, et al. (2000) Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Phisiol-Renal 278: F667-F675.
46. Hersey P, Watts RN, Zhang XD, Hackett J, (2009) Metabolic Approaches to Treatment of Melanoma. Clin Cancer Res 15: 6490-6494.
47. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, et al. (2006) Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 66: 5934-5940.
48. Wang J, Lv XW, Shi JP, Hu XS, (2006) Ceramide induces apoptosis via a peroxisome proliferator-activated receptor gamma-dependent pathway. Apoptosis 11: 2043-2052.
49. Menendez JA, Lupu R, (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
50. Colucci S, Mori G, Vaira S, Brunetti G, Greco G, et al. (2005) L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcified Tissue Int 76: 458-465.
51. Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM, (2010) Iron Chelation Therapy in Upper Egyptian Transfusion-dependent Pediatric Homozygous beta-Thalassemia Major Impact on Serum L-Carnitine/Free Fatty Acids, Osteoprotegerin/The Soluble Receptor Activator of Nuclear Factor-kappa beta Ligand Systems, and Bone Mineral Density. J Pediatr Hematol Oncol 32: 267-273.
52. Xie H, Tang SY, Li H, Luo XH, Yuan LQ, et al. (2008) L-Carnitine protects against apoptosis of murine MC3T3-E1 osteoblastic cells. Amino Acids. 35: 419-423.